Joydeep Mukhoty

CEO

India’s pharmaceutical healthcare products manufac­turing ecosystem has evolved into one of the most sig­nificant pillars of the country’s healthcare economy. Beyond its established strength in generics and large-scale manufacturing, the industry is seeing greater emphasis on specialty therapies, differentiated formulations, regulatory compliance and wider access to medicines.

As healthcare infrastructure expands beyond metros, manufacturers and pharmaceutical marketers are also being challenged to take quality products deeper into underserved markets while improving convenience for patients. Operating at this intersection is Insight Medicare LLP, a pharmaceutical and healthcare products company established in September 2019.

With a portfolio spanning critical care and select products across gynaecology, orthopaedics, cardio-diabetes and surgical care, the company is building its business around two priorities: improving the way established therapies are delivered and widening their availability across interior markets.

Its approach has been shaped by direct engagement with healthcare professionals, an understanding of changing treatment requirements and the belief that pharmaceutical innovation need not always begin with a new molecule. It can equally come from making an existing therapy more convenient for the patient.

From Industry Experience to a Market-Led Business

Insight Medicare traces its beginnings to the extensive pharmaceutical industry experience of its CEO, Joydeep Mukhoty, built over years of working with Indian and multinational companies. Soon after its incorporation, however, the company found itself navigating an unprecedented business environment as COVID-19 disrupted pharmaceutical operations, transportation and supply chains across the country.

Responding to the immediate needs of the market, Insight Medicare quickly mobilized its sourcing and distribution capabilities to supply sanitizers, masks and PPE kits during the first wave, serving organizations such as Tata Metaliks, Castrol India, M-Junction, Lexmark and Air India.

As healthcare requirements shifted during the subsequent wave, the company adapted once again, focusing on pharmaceutical products required by hospitals and healthcare professionals. What began as a response to an extraordinary market situation ultimately strengthened Insight Medicare’s procurement capabilities, institutional relationships and credibility within the healthcare ecosystem.

With the return of regular operations, the company built on this foundation to expand its critical-care portfolio and establish a wider market presence across Maharashtra, Odisha and Chhattisgarh.

Bringing Patient Convenience into Product Development

The company’s product strategy is closely linked to an issue its management repeatedly encountered in conversations with doctors: patients do not always continue prescribed therapies. While affordability can be a factor, Insight Medicare identified ease of administration as another practical concern, particularly for people who already consume multiple medicines.

This led the company to examine how conventional formulations could be presented differently without losing sight of cost, clinical relevance or market acceptance.

Calcium supplementation reflects Insight Medicare’s focus on improving patient convenience. Recognizing that pregnant women and older patients may already be taking multiple medicines, the company introduced an effervescent calcium formulation as an easier alternative to conventional tablets.

It has applied a similar approach to vitamin C and an orosoluble iron formulation designed to dissolve in the mouth. “Through such formats, Insight Medicare aims to improve convenience, absorption and bioavailability while addressing practical patient needs. Its products are manufactured at WHO-GMP-certified facilities and supported by applicable quality-control documentation”, shares Joydeep.

Taking Specialty Products Beyond Established Pharma Markets

Insight Medicare has also aligned its expansion with a structural change taking place in Indian healthcare. Specialist doctors and younger medical professionals are increasingly establishing practices and hospitals in interior and micro-interior locations.

As treatment capabilities improve in these markets, patients who might previously have been referred to larger cities can access more specialized care closer to home. For pharmaceutical companies, this creates a corresponding need to ensure that critical-care and specialty products reach these emerging healthcare centres.

The company has consequently deployed field personnel in smaller territories while developing a district-level approach to distribution. Markets are mapped to identify retail counters, assess where Insight Medicare products are available and locate gaps that need to be addressed.

Existing distributors remain part of this system, but the company is also evaluating dedicated delivery vehicles to reach outlets that conventional networks may not service consistently. “This focus on last-mile availability is central to our growth strategy: building demand through doctors has limited value unless the prescribed product can be found at the retail counter when a patient needs it”, speaks Joydeep.

Building the Next Phase on Technology, Talent and Reach

Insight Medicare’s future roadmap brings together distribution expansion, digital engagement, talent development and differentiated formulations. Software-based monitoring is being used to track field execution more closely and reduce the gap between strategies developed by management and their implementation across territories.

Within regulatory boundaries, the company is also using digital channels for eligible nutritional and FSSAI-regulated products, while WhatsApp API-based communication supports engagement with its network of healthcare professionals.

Going forward, Insight Medicare intends to deepen retail coverage, strengthen its presence in interior and micro-interior markets and continue exploring patient-friendly delivery systems for established molecules.

In a pharmaceutical market where scale alone does not guarantee access, the company is positioning itself around a more grounded proposition: understand what healthcare professionals require, make therapies easier for patients to use, and ensure those products are available wherever healthcare delivery is moving.